Reviewer's report
Title:Long-term follow-up with leukocytapheresis re-treatment in patients with
chronically active inflammatory bowel disease
Version: 1Date:21 March 2010
Reviewer: Abbi Saniabadi
Reviewer's report:
Manuscript number 1290099603578712 by DR Lindberg and colleagues, title:
Long-term follow-up with leukocytapheresis re-treatment in patients with
chronically active inflammatory bowel disease.
1. In this manuscript, DR Lindberg and colleagues describe an innovative
therapeutic intervention which they have used in patients with inflammatory
bowel disease, a debilitating chronic condition that afflicts millions throughout the
world. Essentially, it is a non-drug based therapeutic intervention which is most
intriguing. As virtually all known drugs used to treat gastrointestinal disorders can
cause serious adverse side effects, the strategy described here should be most
welcomed by both the physicians and patients. Further, none of the hitherto
reports has efficacy outcomes over a long period of time. Therefore, the
long-term observations by the authors should benefit the impact of this report as
well.
The manuscript is well written throughout.
2. My information suggests that the GMA used in this study removes myeloid
linage leucocytes (granulocytes and monocytes), regulatory lymphocytes are
spared. Accordingly, the title of this paper should read better as: “Long-term
follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with
chronically active inflammatory bowel disease.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
This is an academic report and in my view, the only beneficiaries are the patients
and the physicians in the area dealt with. This has been the basis of my
evaluation.
Reviewer's report
Title:Long-term follow-up with leukocytapheresis re-treatment in patients with
chronically active inflammatory bowel disease
Version: 1Date:21 March 2010
Reviewer: Abbi Saniabadi
Reviewer's report:
Manuscript number 1290099603578712 by DR Lindberg and colleagues, title:
Long-term follow-up with leukocytapheresis re-treatment in patients with
chronically active inflammatory bowel disease.
1. In this manuscript, DR Lindberg and colleagues describe an innovative
therapeutic intervention which they have used in patients with inflammatory
bowel disease, a debilitating chronic condition that afflicts millions throughout the
world. Essentially, it is a non-drug based therapeutic intervention which is most
intriguing. As virtually all known drugs used to treat gastrointestinal disorders can
cause serious adverse side effects, the strategy described here should be most
welcomed by both the physicians and patients. Further, none of the hitherto
reports has efficacy outcomes over a long period of time. Therefore, the
long-term observations by the authors should benefit the impact of this report as
well.
The manuscript is well written throughout.
2. My information suggests that the GMA used in this study removes myeloid
linage leucocytes (granulocytes and monocytes), regulatory lymphocytes are
spared. Accordingly, the title of this paper should read better as: “Long-term
follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with
chronically active inflammatory bowel disease.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
This is an academic report and in my view, the only beneficiaries are the patients
and the physicians in the area dealt with. This has been the basis of my
evaluation.
Please review this paper.
user
Reviewer's report
Title:Long-term follow-up with leukocytapheresis re-treatment in patients with
chronically active inflammatory bowel disease
Version: 1Date:21 March 2010
Reviewer: Abbi Saniabadi
Reviewer's report:
Manuscript number 1290099603578712 by DR Lindberg and colleagues, title:
Long-term follow-up with leukocytapheresis re-treatment in patients with
chronically active inflammatory bowel disease.
1. In this manuscript, DR Lindberg and colleagues describe an innovative
therapeutic intervention which they have used in patients with inflammatory
bowel disease, a debilitating chronic condition that afflicts millions throughout the
world. Essentially, it is a non-drug based therapeutic intervention which is most
intriguing. As virtually all known drugs used to treat gastrointestinal disorders can
cause serious adverse side effects, the strategy described here should be most
welcomed by both the physicians and patients. Further, none of the hitherto
reports has efficacy outcomes over a long period of time. Therefore, the
long-term observations by the authors should benefit the impact of this report as
well.
The manuscript is well written throughout.
2. My information suggests that the GMA used in this study removes myeloid
linage leucocytes (granulocytes and monocytes), regulatory lymphocytes are
spared. Accordingly, the title of this paper should read better as: “Long-term
follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with
chronically active inflammatory bowel disease.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
This is an academic report and in my view, the only beneficiaries are the patients
and the physicians in the area dealt with. This has been the basis of my
evaluation.
assistant